In exciting news for Quartesian and their clients, an agreement with Medidata will now provide complete access to the unified Medidata Clinical Cloud® and their advanced analytics platform.
“We are delighted that Quartesian is benefiting from Medidata’s unified platform and advanced analytics,” said Glen de Vries, Medidata president and co-founder. “We share Quartesian’s mission of helping life sciences companies advance their scientific goals. It’s exciting to provide them with tools and data insights that help achieve it, ultimately accelerating the delivery of new therapies to patients.”
This new enterprise license agreement marks a milestone for Quartesian, positioning them as the go-to resource for Medidata Rave®. Rave is the world’s leading solution for capturing, managing and reporting patient data. Now, Quartesian will be able to offer an even broader set of data capture and management capabilities to their customers.
Quartesian experienced a significant increase in demand for high quality, cost-efficient clinical data services for many of its life sciences customers and CRO partners—which led to this agreement with Medidata. After completing a rigorous training process, Quartesian gained accreditations to market Medidata products, including Rave, Medidata Coder®,Medidata TSDV, Medidata Balance®, which unifies randomization, trial supply management and EDC into one system and Medidata Patient Cloud ePRO, a mobile platform for patient reported outcomes.
With its growing expertise in key Medidata technology for clinical research, Quartesian’s place is now cemented as the leading provider of high quality, timely clinical data services delivered with the best industry value. Quartesian clients will now be able to make more informed decisions earlier, and faster.